Ambu dampens hopes for proclaimed growth driver

Expectations for the medtech firm’s single-use duodenoscope product haven’t been met, which is one of the reasons chief executive Britt Meelby Jensen announced a guidance downgrade last week.

Photo: Ambu/PR

Ambu’s future growth will come from a wide variety of endoscopes its portfolio – but the medtech firm’s single-use duodenoscope will no longer be leading the charge despite having been heralded as its next great growth driver.

Under the new leadership of chief executive Britt Meelby Jensen, who joined the firm a little over two months ago, Ambu has just lowered its full-year expectations last week, and is now counting on organic sales growth of no less than 4% from the previous 13%+ forecast.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs